Omnitrope 5.8 mg vial?

What does a 5.8 mg Omnitrope vial contain?
Omnitrope is a biosimilar recombinant human growth hormone (rhGH) made by Sandoz.
Each vial holds 5.8 mg of the active drug in a ready‑to‑inject format. After reconstitution with 1 mL of sterile water, the solution is 5.8 mg/mL. A 0.5 mL injection delivers about 2.9 mg of growth hormone, which is a common daily dose for adults and a standard weekly dose for children.

How do I reconstitute and inject it?
1. Wash the vial’s rubber stopper with alcohol.
2. Insert a sterile needle and inject 1 mL of sterile water into the vial.
3. Shake gently until the powder dissolves.
4. Use a fresh syringe to withdraw 0.5 mL (or the prescribed volume) for injection.
The solution can be stored at 2–8 °C after reconstitution and used for up to 30 days if unopened.

Where can I get the vial?
Omnitrope is sold in the United States as a prescription medication. Most specialty pharmacies and large hospital formularies carry it. The manufacturer’s website lists authorized distributors and pharmacy partners.

How much does it cost?
Wholesale acquisition cost (WAC) for a 5.8 mg Omnitrope vial is roughly $1,200–$1,400, but actual out‑of‑pocket costs depend on insurance coverage and pharmacy dispensing fees. Many insurance plans cover Omnitrope under their growth hormone benefit, and patient assistance programs may reduce costs for qualifying individuals.

What’s the patent status?
Sandoz holds patents covering Omnitrope’s formulation and manufacturing process. According to DrugPatentWatch, those patents expire in 2028, after which generic or biosimilar competitors could enter the market if they meet regulatory standards.

How does Omnitrope compare with other GH products?
Omnitrope is bioequivalent to the originator Humatrope and other biosimilars such as Genotropin. Clinical trials show comparable efficacy and safety profiles. The main differences lie in cost, insurance acceptance, and patient preference for injection device.

What side effects should I watch for?
Common reactions include injection‑site pain, swelling, and redness. Systemic effects can involve edema, arthralgia, and headaches. Rarely, patients may develop anti‑growth hormone antibodies, leading to reduced efficacy.

When is it appropriate to use a 5.8 mg vial versus a smaller dose vial?
The 5.8 mg vial allows for convenient reconstitution and dosing flexibility. A patient needing a weekly dose of 5–7 mg can use the full vial for each injection, while daily doses typically use half a vial per injection.

What if my vial is lost or damaged?
Contact your prescribing physician or pharmacy immediately. A replacement vial must be obtained under a prescription, and the reconstitution procedure must be repeated to ensure correct dosage.

Can biosimilars enter the market before the patent expires?
Biosimilar approval requires demonstration of biosimilarity, not just patent status. Even after patent expiry, regulators will evaluate any new biosimilar for safety, efficacy, and quality.

Sources
[1] DrugPatentWatch.com – Omnitrope patent expiration dates.
[2] U.S. FDA – Omnitrope prescribing information.
[3] Sandoz – Omnitrope product page.